Publication for HOXA6 and HOXA9

Species	Symbol	Function*	Entrez Gene ID*	Other ID	Gene coexpression	CoexViewer
hsa	HOXA6	homeobox A6	3203			[link]
hsa	HOXA9	homeobox A9	3205

Pubmed ID	Priority	Text
28130639	0.98	HOXA6, HOXA9, PENK, UPK3A and IGF2BP1) could successfully identify recurrent tumors and could be used as epigenetic biomarkers to effectively predict a pattern of global DNA methylation in meningioma.
	0.97	HOXA6, HOXA9, OTX2, MAL2, and PAX3.
	0.95	HOXA6, and HOXA9 were reported in aggressive meningiomas by several studies but our analysis did not identify these genes as important predictors of outcome.
	0.90	HOXA6, and HOXA9, there were significant differences with increased levels of methylation in the MM-UNFAV group compared to MM-FAV group (findings limited to the validation dataset) (Online resource 9) confirming the findings in the literature.
19549311	0.98	HOXA9, HOXA7, HOXA5 and HOXA3 were found to be generally upregulated in samples carrying MLL translocation, both in ALL and AML, while HOXA11 and HOXA6 showed common overexpression in AML/MLL+ cases.
26517675	0.98	HOXA6 (P = 3.34 x 10-7), HOXA9 (P = 4.72 x 10-8), HOXA10 (P = 5.83 x 10-8), HOXB2 (P = 5.95 x 10-8), HOXB3 (P = 5.61 x 10-5), HOXB4 (P = 1.37 x 10-6), HOXB5 (P = 3.90 x 10-6), HOXB6 (P = 2.65 x 10-3), HOXB7 (P = 2.21 x 10-3), HOXB8 (P = 1.78 x 10-2), MEIS1 (P = 6.18 x 10-7), and PBX3 (P = 5.02 x 10-4).
31964111	0.98	HOXA6, HOXA9, and HOXA11, induces silencing and downregulation of target tumor suppressors.
26444494	0.97	HOXA6, HOXA7, HOXA9 and HOXA10 compared with NPM1 wild-type samples in the The Cancer Genome Atlas (TCGA) cohort (Supplementary Fig. 4).
	0.88	HOXA6, HOXA7, HOXA9 and HOXA10 (Supplementary Data 4).
	0.74	HOXA6, HOXA7, HOXA9 and HOXA10 in the LSC epigenetic signature (Fig. 1b-d and Supplementary Data 2).
23349797	0.97	HOXA6 and HOXA9) tend to coincide with the binding sites of polycomb repressive complexes (PRC) in early developmental stages.
	0.94	HOXA6 and HOXA9 has also been implicated in recurrent meningiomas according to another study.
26101774	0.97	HOXA6, HOXA9, PENK, UPK3A, and IGF2BP1) was proposed.
31426381	0.96	HOXA6 expression in pro-B ALL (fold change = 2.01); (iii) HOXA7 expression in AML (fold change = 2.03); (iv) HOXA9 expression in AML (fold change = 2.99) and pro-B ALL (fold change = 7.21); and (v) HOXA10 expression in AML (fold change = 2.17) and pro-B ALL (fold change = 4.80).
	0.96	HOXA6, HOXA7, HOXA9, and HOXA10 were significantly correlated with poor overall survival (OS, P < 0.05) in all of the AML patients (Figure 3).
	0.87	HOXA6, HOXA7, HOXA9, and HOXA10 was upregulated in patients with leukemia (Table 1).
20339440	0.96	HOXA6, HOXA7, HOXA9, HOXB3, HOXB5, HOXB6, and HOXB7 as well as the non-clustered (type II) homeobox genes, MEIS1 and PBX3.
29163771	0.96	HOXA6 or HOXA9 alone has little effect on AML cells, but their double knock-down induces cell death and also increases their sensitivity to cytarabine.
29221119	0.96	HOXA6, HOXA7, HOXA9, HOXB9 and MEIS1 were observed in NPM1 mutated cells, as well as AML with MLL abnormalities.
29770198	0.96	HOXA6, HOXA9, PENK, UPK3A, and IGF2bP1) was reported to provide 80 to 90% sensitivity and specificity in predicting recurrence of meningiomas, independent of tumor grade .
22498108	0.95	HOXA6 and HOXA9) were silenced in all samples of this study.
25539595	0.94	HOXA6, HOXA9, HOXA10 and HOXB4 (Figure 4).
	0.90	HOXA6, HOXA7, HOXA9, HOXA10, HOXB5 and HOXB6 distinguished leukemic cells of the M5a and M5b FAB subtypes from the matched normal counterparts, represented by the sorted M3 and M4 population, respectively (Additional file 8: Figure S7A and 7B).
27183470	0.94	HOXA6, HOXA7 and HOXA9 expression in EB or FL cells treated with RA and AM580 (mean +/- SEM from n=4 independent experiments, see Supplementary Table 7 for statistics source data).
25266220	0.92	HOXA6, HOXA9, PBX3 and MEIS1), whose common expression signature was shown to influence overall survival in CN-AML.
26485654	0.91	HOXA6, HOXA7, HOXA9, HOXA10 and HOXA11 from HOXA-cluster.
21339820	0.79	HOXA6, HOXA7, HOXA9 and HOXA10 (Table 6).
31970090	0.76	HOXA6, HOXA9, PENK, UPK3A, and IGF2bP1).
20068170	0.65	HOXA9 expression in our tumor sets, also demonstrated a substantially lower correlation coefficient in the samples from Sun et al. Since HOXA6 and HOXA13 do not correlate with HOXA9 expression in all 3 tested tumor sets, a mechanism of chromosomal amplification encompassing the entire HOXA locus may not adequately explain the presence of such transcriptionally-active domains.
29928480	0.65	HOXA6, HOXA9 and HOXA10.
31333881	0.54	HOXA6, HOXA7, HOXA9, and HOXB9 genes and the MEIS1 and PBX3 genes.